Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis

<div>Validation of the key candidate proteins in TCGA-GBM-540 dataset (a total of 504 patients; 36 patients lacking survival data were omitted from the analysis). Nine special proteins (DHX9, HNRNPR, RPL3, HNRNPA3, SF1, DDX5, EIF5B, BTF3, and RPL8), which were downregulated after TMZ treatment and related to both overall survival (a) and progress-free survival (b) probability of GBM patients.</div>

BioMed Research International

fig5

Figure 5

Figure 5: Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis 

Figure 5 | Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis 